American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

June 19, 2017June 19, 2017

Adcetris-Gemzar Combo Yields High Complete Response Rates in Young Hodgkin’s Lymphoma Patients, Study Finds

News

Combining the monoclonal antibody-drug conjugate Adcetris (brentuximab vedotin) with the chemotherapy drug Gemzar (gemcitabine) results in a high complete response rate in children and young adults with relapsed or refractory ... Read more

June 9, 2017June 9, 2017

Community Oncologists Present 40 Abstracts on New Cancer Research at ASCO 2017

News

Community oncologists affiliated with the U.S. Oncology Network and U.S. Oncology Research shared findings from about 40 data presentations covering new approaches to several cancer specialties at the 53rd annual meeting of the American ... Read more

June 8, 2017June 8, 2017

T-Cell Therapy JCAR017 Eliminates Tumor Cells in Half of DLBCL Patients in Phase 1 Trial

News

Recently announced data from a Phase 1 trial for investigational T-cell therapy JCAR017 shows a high response rate for patients with relapsed or refractory CD19+ aggressive B-cell non-Hodgkin lymphoma (NHL), ... Read more

June 2, 2017June 2, 2017

Potential Treatment for a Number of Blood Cancers, ASN002, Enters Phase 2 Trial

News

Following positive results in a dose–escalation trial with non-Hodgkin’s lymphoma (NHL) patients, a Phase 2 trial will now evaluate a new kinase inhibitor, ASN002, in the treatment of several hematological ... Read more